<DOC>
	<DOCNO>NCT00598104</DOCNO>
	<brief_summary>This study evaluate safety efficacy QAX576 asthma attack adults moderate persistent allergic asthma</brief_summary>
	<brief_title>Safety Efficacy QAX576 Adults With Moderate Persistent Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>History asthma attack Taking inhaled corticosteroid Nonsmoking Women childbearing potential History respiratory disease asthma History severe allergy food drug Previous use monoclonal antibody Very low high body weight Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Asthma , interleukin-13</keyword>
</DOC>